Literature DB >> 25349947

Effect of neoadjuvant chemotherapy on resectability of stage III and IV hepatoblastoma.

R Venkatramani1, J E Stein, A Sapra, Y Genyk, V Jhaveri, M Malogolowkin, L Mascarenhas.   

Abstract

BACKGROUND: The potential for surgical resection of primary hepatoblastoma tumours was assessed at diagnosis, and after two and four cycles of neoadjuvant chemotherapy.
METHODS: Available radiographic images for patients with stage III and IV hepatoblastoma diagnosed between 1991 and 2008 were reviewed. The extent of disease was determined at diagnosis using the PRETEXT staging system, and after two and four cycles of therapy by POST-TEXT staging. Tumour resectability based on radiographic studies was assessed independently by two surgeons with expertise in hepatic surgery who were blinded to treatment and clinical outcome.
RESULTS: Radiographic images from 20 patients with hepatoblastoma were reviewed. Six of 20 tumours were downstaged after two cycles, and three additional tumours were downstaged following four cycles. All PRETEXT stage III and IV tumours were determined to be surgically unresectable at diagnosis. The number of tumours considered unresectable decreased from 16 of 20 at diagnosis to seven of 20 after two cycles, and to four of 20 after four cycles. Five of the seven tumours that were unresectable after two cycles, and all four tumours that were unresectable after four cycles would have qualified for liver transplant based on radiographic studies.
CONCLUSION: The majority of stage III and IV hepatoblastomas achieved radiographic resectability after two cycles of chemotherapy. There may be an opportunity for earlier surgical intervention and potential for a reduction in chemotherapy in a considerable number of patients.
© 2014 BJS Society Ltd. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25349947     DOI: 10.1002/bjs.9681

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  7 in total

1.  [Therapeutic effect and clinical cost of multi-disciplinary team model of hepatoblastoma in children].

Authors:  Y X Gao; Q Sun; H Li; Y Xie; H X Yao; W H Zhao
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-09

2.  Repeat hepatectomy for pediatric recurrent chemotherapy-resistant hepatoblastoma: a report of 18 cases.

Authors:  Xiaoran Li; Zheng Wang; Dongpo Zhang; Di Zhao; Jindong Ye; Weihong Duan; Liuxin Duan; Quanda Liu
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-29       Impact factor: 4.322

3.  Application of 3D Simulation Software in Chemotherapy and Hepatoblastoma Surgery in Children.

Authors:  Jie Liu; Wenli Xiu; Guangqi Duan; Qian Dong
Journal:  Front Surg       Date:  2022-06-01

4.  m6A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma.

Authors:  Li Liu; Jing Wang; Guifeng Sun; Qiong Wu; Ji Ma; Xin Zhang; Nan Huang; Zhixuan Bian; Song Gu; Min Xu; Minzhi Yin; Fenyong Sun; Qiuhui Pan
Journal:  Mol Cancer       Date:  2019-12-23       Impact factor: 27.401

5.  Assessment of Survival of Pediatric Patients With Hepatoblastoma Who Received Chemotherapy Following Liver Transplant or Liver Resection.

Authors:  Jincheng Feng; Ying He; Lai Wei; Dong Chen; Huifang Yang; Rumeng Tan; Zhishui Chen
Journal:  JAMA Netw Open       Date:  2019-10-02

6.  Incidence trends and survival prediction of hepatoblastoma in children: a population-based study.

Authors:  Jincheng Feng; Georgios Polychronidis; Ulrike Heger; Giovanni Frongia; Arianeb Mehrabi; Katrin Hoffmann
Journal:  Cancer Commun (Lond)       Date:  2019-10-24

7.  Analysis of factors related to recurrence of paediatric hepatoblastoma - a single Centre retrospective study.

Authors:  Wei Yang; Yiwei Chen; Yijin Huang; Huanmin Wang
Journal:  BMC Pediatr       Date:  2019-12-10       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.